Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oncternal Therapeutics, Inc.

0.5266
+0.0000
Volume:- -
Turnover:- -
Market Cap:1.56M
PE:-0.05
High:0.5266
Open:0.5266
Low:0.5266
Close:0.5266
Loading ...

Oncternal Therapeutics Inc Intent To Voluntarily Delist From Nasdaq And Deregister With SEC

Reuters
·
08 Mar

Top Premarket Decliners

MT Newswires Live
·
25 Nov 2024

Oncternal Therapeutics to Cut Most of Its Workforce

Dow Jones
·
15 Nov 2024

Oncternal Therapeutics Inc: Announces Workforce Reduction Effective December 2, 2024

THOMSON REUTERS
·
15 Nov 2024

Oncternal Therapeutics Inc: Four Oncternal Employees Will Remain in a Part-Time Capacity in Connection With Exploration of Strategic Alternatives

THOMSON REUTERS
·
15 Nov 2024

Oncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview

Reuters
·
06 Nov 2024

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

THOMSON REUTERS
·
22 Oct 2024

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire
·
22 Oct 2024

Oncternal Therapeutics Cuts Jobs, Discontinues Product Development Amid Business Review

Dow Jones
·
13 Sep 2024

BRIEF-Oncternal Therapeutics Workforce Reduction Of About 10 Employees

Reuters
·
13 Sep 2024

Oncternal Therapeutics : Workforce Reduction of About 10 Employees

THOMSON REUTERS
·
13 Sep 2024

Oncternal Therapeutics : in Connection With Workforce Reduction, Salim Yazji Will Cease Serving as Chief Medical Officer

THOMSON REUTERS
·
13 Sep 2024

Sector Update: Health Care Stocks Rise in Thursday Trading

MT Newswires Live
·
13 Sep 2024

Oncternal Therapeutics Cut to Hold From Buy by Brookline Capital

Dow Jones
·
12 Sep 2024

Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall

MT Newswires Live
·
12 Sep 2024

Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall

MT Newswires Live
·
12 Sep 2024

Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy

MT Newswires Live
·
12 Sep 2024

Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy

MT Newswires Live
·
12 Sep 2024

BUZZ-Oncternal hits record low on plans to scrap studies, explore strategic alternatives;

Reuters
·
12 Sep 2024

Oncternal Therapeutics Shares Hit Record Low as Co to Scrap Studies, Explore Strategic Alternatives, Last Down 58.6% at $1.72

THOMSON REUTERS
·
12 Sep 2024